MARKET WIREYahoo Finance • 22h ago
Optimi Health Establishes Australian SubsidiaryYahoo Finance report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
Why OPTH Stock dropped -7.05% Today — RQD Quant Desk Flash
$2.24 -7.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.21
Optimi Health Corp. (OPTH) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $13.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on OPTH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is OPTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Optimi Health Corp. (NASDAQ: OPTH) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.24 (-7.05% 1D, market cap $13.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OPTH ranks #346 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does OPTH compare to DARE and ALLR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OPTH carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DARE (Dare Bioscience Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M) and ALLR (Allarity Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M). Among the 5-stock peer group, OPTH leads on earnings multiple (N/A) while DARE leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for OPTH?
▼
For Optimi Health Corp. (OPTH), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #346 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.21 (-1.46%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OPTH)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY OPTH SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)
SEC XBRL Trailing 12 Months: 0% FCF Margin ($386.4K FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$3.50-4% Next Q
54
Q2 (-2Q)Grade C-$3.36-9.5% Next Q
51
Q3 (-1Q)Grade D$3.04-26.3% Next Q
49
CurrentGrade D$2.24-6.1% Hist 90D α
46
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a OPTH Turnaround Squeeze
While OPTH currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.15) and Max Pain ($2.35) forces dealer call-delta covering toward $6.72.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $OPTH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OPTH Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OPTH Stock dropped -7.05% Today — RQD Quant Desk Flash
Optimi Health Corp. (OPTH) dropped -7.05% to $2.24, trading at 5% of its 52-week range ($2.02 – $6.4). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($2.02 – $6.4) with RSI-14 at 23.6 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.24 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $386381 annual free cash flow.
Live OPTH Headlines & Catalysts
MARKET WIREStocktwits • 1d ago
SRx Health Decided To Invest In A Psychedelic Drug Company That Just Went Public – Here’s What Aided The DecisionStocktwits report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMugglehead Investment Magazine • 1d ago
Optimi Health reports finished MDMA batch ahead of Australian exportMugglehead Investment Magazine report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
Optimi Health to Present at the ThinkEquity ConferenceGlobeNewswire report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Psychedelic medicine is approaching a turning point. The U.S. needs the right infrastructure to be readyYahoo Finance report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development EntityGlobeNewswire report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
Optimi Health Completes MDMA Production for Phase 3 PTSDGlobeNewswire report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 14d ago
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in AustraliaBatch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia Health Canada-authorized trial to evaluate efficacy a
MARKET WIREBenzinga • 14d ago
Optimi Health Completes Latest Production Batch Of Its MDMA Finished Drug Product; Proposed Phase 3 Trial Expected To Begin In 2027The capsules were manufactured at Optimi’s GMP facility in Princeton, British Columbia, under its Health Canada Drug Establishment Licence, and are expected to supply three programs: the recently announced proposed
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OPTH)
- ✓Walkthrough of OPTH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OPTH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.16%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.60H $2.60L $2.24C $2.24VOL 59.3K
RES: $5.20SUP: $1.93SMA50: $4.15SMA200: $4.56
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OPTH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on OPTH today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OPTH. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OPTH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OPTH)
Health Care Rank #346 of 1015
⚔️ DARE vs OPTH Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OPTH vs. DARE, ALLR, CTXR, BFRI)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Optimi Health Corp. (OPTH) ranks #346 by composite RQD confidence (46/100, grade D) and #860 by equity capitalization ($13.8M). Within this direct 5-issuer industry benchmark cohort, OPTH leads on earnings valuation at N/A trailing P/E, while DARE leads on capital efficiency and profitability with -35.0% ROIC and 71.3% gross margin. OPTH currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OPTH
ACTIVE
Optimi Health Corp. | D | 46/100 | — | — | — | -7.05% | $13.8M | Benchmark Subject |
| DARE Dare Bioscience Inc. | D- | 36/100 | — | 71.3% | -35.0% | -6.37% | $13.8M | /dare-vs-opth → |
| ALLR Allarity Therapeutics Inc. | E | 32/100 | — | — | -35.0% | +12.33% | $13.8M | /allr-vs-opth → |
| CTXR Citius Pharmaceuticals Inc. | D- | 40/100 | — | — | -35.0% | +7.44% | $14.4M | /ctxr-vs-opth → |
| BFRI Biofrontera Inc. | E | 26/100 | — | — | -35.0% | -0.32% | $13.0M | /bfri-vs-opth → |
2. OPTH Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTOptimi Health Corp. (OPTH) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $13.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. OPTH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OPTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Optimi Health Corp. (NASDAQ: OPTH) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.24 (-7.05% 1D, market cap $13.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OPTH ranks #346 in composite RQD confidence.
How does OPTH compare to DARE and ALLR in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OPTH carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DARE (Dare Bioscience Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M) and ALLR (Allarity Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M). Among the 5-stock peer group, OPTH leads on earnings multiple (N/A) while DARE leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OPTH?
For Optimi Health Corp. (OPTH), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #346 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OPTH trading relative to its 50-day, 200-day, and 52-week technical levels?
OPTH last traded at $2.24 (-7.05% on volume of 21,765 shares), positioning the stock -46.02% below its 50-day simple moving average ($4.15) and -50.88% below its 200-day simple moving average ($4.56). Across its 52-week range of $2.02 to $6.40, OPTH sits at the 5.0% percentile with a 14-day RSI of 23.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.96 to $2.52).
ROARABLE RATING BRIEF • RQD 46/100 (D)
✓ SEC XBRL & RQD VERIFIED
OPTH — Optimi Health Corp.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
Optimi Health Corp. (OPTH) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $2.24 (-7.05% 1D, market capitalization $13.8M).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Optimi Health Corp. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, . The company's market capitalization is $0.0B. Per the news wire, the company has reported a finished MDMA batch ahead of an Australian export and established an Australian subsidiary, Optimi Australia Pty Ltd, as a distribution and business development entity.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.02 – $6.40 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies cannot be mapped from the source data. Sector correlations are not quantified beyond the reported Beta of 1.0. A prospective investor should watch whether the Australian export and distribution entity converts into reported revenue, since the source data supplies no financial statements to confirm it.
- Key Question #1: Can OPTH sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $6.40 52-week high?
- Key Question #3: How sensitive is OPTH's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
OPTH Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Optimi Health Corp. (OPTH) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 22h ago
Optimi Health Establishes Australian Subsidiary Yahoo Finance report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stocktwits • 1d ago
SRx Health Decided To Invest In A Psychedelic Drug Company That Just Went Public – Here’s What Aided The Decision Stocktwits report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Mugglehead Investment Magazine • 1d ago
Optimi Health reports finished MDMA batch ahead of Australian export Mugglehead Investment Magazine report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
Optimi Health to Present at the ThinkEquity Conference GlobeNewswire report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Psychedelic medicine is approaching a turning point. The U.S. needs the right infrastructure to be ready Yahoo Finance report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity GlobeNewswire report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
Optimi Health Completes MDMA Production for Phase 3 PTSD GlobeNewswire report covering Optimi Health Corp. (OPTH) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo • 14d ago
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia Health Canada-authorized trial to evaluate efficacy a
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
OPTH Bull vs. Bear Conversation Board — What's Your Call at $2.24?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OPTH 🐻 33% BEARISH CONVICTION
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH
🎯 Target: $2.96 (+22.8%)
📌 Pinned Debate The Forensic Balance Sheet pillar (13/20) reports an Altman Z of 2.5 and Piotroski F of 6/9, indicating the company is not flagged as f
The street is overcomplicating Optimi Health Corp. (OPTH). The Forensic Balance Sheet pillar (13/20) reports an Altman Z of 2.5 and Piotroski F of 6/9, indicating the company is not flagged as financially distressed on forensic measures.. With an RQD score of 46/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $2.60.
VolSurface_Trader 🐂 BULL
Both sides have a point here — OPTH's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH
🎯 Target: $1.95 (-19.1%)
Spot @ $2.41 The Whale 13F Flow pillar scores 3/20 alongside 0% ROIC and 0% FCF yield, showing weak institutional conviction and no reported return
Careful chasing OPTH at $2.41. The Whale 13F Flow pillar scores 3/20 alongside 0% ROIC and 0% FCF yield, showing weak institutional conviction and no reported return on capital.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.95 on multiple compression.